$22.34
-1.25 (-5.30%)
Open$23.48
Previous Close$23.59
Day High$23.51
Day Low$21.75
52W High$50.20
52W Low$6.50
Volume—
Avg Volume802.8K
Market Cap1.20B
P/E Ratio—
EPS$-293.09
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+55.5% upside
Current
$22.34
$22.34
Target
$34.74
$34.74
$25.90
$34.74 avg
$38.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.07M | 27.10M | 30.53M |
| Net Income | 5.84M | 4.59M | 6.02M |
| Profit Margin | 20.1% | 16.9% | 19.7% |
| EBITDA | 8.15M | 7.65M | 7.71M |
| Free Cash Flow | 6.21M | 7.09M | 6.33M |
| Rev Growth | +18.1% | +12.4% | +4.7% |
| Debt/Equity | 0.64 | 0.68 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |